M. Leinonen - Concepedia

Author

M. Leinonen

Orion Corporation (Finland)

Also Known As

K Laurikainen, M Leinonen, M. Leinonen, Minna Leinonen

Publications

732

Citations

H-Index

Concepts

All Affiliations

Orion Corporation (Finland)Tampere University Hospital Helsinki University Hospital Turku University Hospital

About

M. Leinonen is an author at Orion Corporation (Finland) specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	256
2	Health Sciences	1	1	79
3	Allergy	1	1	17
4	Immunology	1	1	79
5	Neurology	1	1	84

M. Leinonen

Publications

664

Citations

H-Index

Page 1

	Year	Citations
Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study) Werner Poewe, Günther Deuschl, A. Gordin, Acta Neurologica Scandinavica	2002	208
Twelve‐month safety of entacapone in patients with Parkinson’s disease Vilho V. Myllylä, E.‐R. Kultalahti, Helena Haapaniemi, European Journal of Neurology Psychoactive DrugEntacapone PatientsPharmacologyNeuropharmacologyPharmacotherapy	2001	84
The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease Jan Larsen, J Worm-Petersen, Å Sidén, European Journal of Neurology	2003	80
Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). Heikki Joensuu, Mikael Eriksson, J. Hatrmann, Journal of Clinical Oncology Surgical OncologyCancer ManagementImmunologyPathologyAnnual Meeting Proceedings	2011	79
Pre-Eclampsia Is a Risk Factor of Carotid Artery Atherosclerosis L. Haukkamaa, Leena Moilanen, Anna Kattainen, Cerebrovascular Diseases	2009	48
Early versus delayed initiation of entacapone in levodopa‐treated patients with Parkinson’s disease: a long‐term, retrospective analysis Helena Nissinen, Mikko Kuoppamäki, M. Leinonen, European Journal of Neurology	2009	32
Response to Imatinib Rechallenge of GIST That Recurs Following Completion of Adjuvant Imatinib Treatment - the First Analysis in the SSGXVIII/AIO Trial Patient Population Peter Reichardt, J. T. Hartmann, Kirsten Sundby Hall, European Journal of Cancer Surgical OncologyFirst AnalysisImatinib RechallengeMedicineAdjuvant Imatinib Treatment	2011	29
Very high quantitative tumor HER2 content and outcome in early breast cancer Heikki Joensuu, Jeff Sperinde, M. Leinonen, Annals of Oncology Tumor BiologyBreast OncologyEarly Breast CancerMedicinePathology	2011	26
Equivalence of Two Steroid-Containing Inhalers: Easyhaler Multidose Powder Inhaler Compared with Conventional Aerosol with Large-Volume Spacer Tuomas Koskela, J. Hedman, Heikki Ekroos, Respiration	2000	21
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial Heikki Joensuu, Liisa Sailas, Tuomo Alanko, Annals of Oncology Advanced Breast CancerBreast OncologyMedicineRandomised TrialPharmacology	2009	21

Page 1